Oculis (OCS) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Phathom Pharmaceuticals (PHAT) has outperformed Oculis (OCS) over the past year, losing 35.5% versus a loss of 56.4%. Over five years, OCS leads with a -11.8% price change compared with -78.1% for PHAT. Phathom Pharmaceuticals is the larger company by market cap ($578.4 million vs $527.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCS | PHAT |
|---|---|---|
| Share price | $8.57 | $7.15 |
| Market cap | $527.50M | $578.44M |
| 1-day change | -1.10% | +0.28% |
| YTD return | -56.63% | -57.02% |
| 1-year return | -56.42% | -35.48% |
| 5-year return | -11.81% | -78.07% |
| Forward P/E | — | 6.63 |
| EPS (TTM) | $-1.74 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.48 | $18.31 |
| 52-week low | $8.30 | $6.52 |
| Distance from 52-week high | -75.16% | -60.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +326.04% | +186.01% |
| Average volume | 257.00K | 1.38M |
| Shares outstanding | 61.59M | 80.90M |
| Employees | 60 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHAT has outperformed OCS by 20.9 percentage points over the past year.
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
OCS vs PHAT FAQ
Which is bigger, Oculis or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $578.44M compared with $527.50M for Oculis (OCS).
Which stock has performed better over the past year, OCS or PHAT?
PHAT returned -35.48% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Oculis and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.